



Alimta[®] (pemetrexed) – New warnings

- On October 11, 2017, the [FDA approved](#) updates to the *Warnings and Precautions* section of the [Alimta \(pemetrexed\)](#) drug label.
- Alimta is indicated for the following:
 - Initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC) in combination with [cisplatin](#).
 - Maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy, as a single agent.
 - Treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy, as a single agent.
 - In combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.
- Information regarding myelosuppression and increased risk of myelosuppression without vitamin supplementation, renal failure, bullous and exfoliative skin toxicity, interstitial pneumonitis, radiation recall, and increased risk of toxicity with [ibuprofen](#) in patients with renal impairment were added to the *Warnings and Precautions* section of the Alimta drug label.
- The Alimta drug label was also updated to conform to the Pregnancy and Lactation Labeling Rule consistent with FDA Draft Guidance for Industry.
- Refer to the Alimta drug label for more details regarding the updates.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.